ARTICLE | Clinical News
ANX-188: Phase III start
November 5, 2012 8:00 AM UTC
This quarter, Adventrx will begin a double-blind, placebo-controlled Phase III trial evaluating ANX-188 in 388 patients with sickle cell disease ages 8-17 years and who are experiencing acute pain typ...